Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q4 2012 · —
Revenue$2.59B$2.59B+17.6% vs Q4 2011 Net Income$762.54M$762.54M+14.6% vs Q4 2011 EPS Diluted$0.47$0.47+9.3% vs Q4 2011 Gross Profit$1,834,993,000+18.5% Operating Incomederived$1,106,808,000+27.6% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Operating Cash Flowderived$706,012,000−27.8% Free Cash Flowderived$436,187,000−54.2% Margins · derivedGross margin70.9%+0.5 pt vs Q4 2011
Operating margin42.8%+3.3 pt vs Q4 2011
Net margin29.5%−0.8 pt vs Q4 2011